Condition:   HIV Dementia
Interventions:   Drug: Lipitor;   Drug: placebo
Sponsors:   University of Pennsylvania;   University of Pennsylvania
Not yet recruiting - verified May 2012

Condition:   HIV Dementia
Interventions:   Drug: Long acting methylphenidate;   Drug: Long acting methylphenidate;   Drug: Matched placebo
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles
Recruiting - verified May 2012

Condition:   Melanoma
Interventions:   Drug: Vemurafenib;   Drug: IL-2;   Drug: Interferon Alpha-2b
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: GSK1265744 Oral;   Drug: GSK1265744 LAP 800mg intramuscular injection;   Drug: GSK1265744 LAP 200mg subcutaneous injection;   Drug: GSK1265744 LAP 200mg intramuscular injection;   Drug: GSK1265744 LAP 400mg intramuscular injection;   Drug: TMC278 LA 1200mg intramuscular injection;   Drug: TMC278 LA 600mg intramuscular injection;   Drug: GSK1265744 LAP 800mg intramuscular injection
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   GlaxoSmithKline
Not yet recruiting - verified May 2012

Conditions:   HIV;   Bone Mineral Density;   Bone Turnover;   Fracture
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified May 2012

Condition:   Tuberculosis
Intervention:  
Sponsors:   Cepheid;   Cepheid;   AIDS Clinical Trials Group;   Centers for Disease Control and Prevention
Recruiting - verified April 2012

Condition:   Cardiovascular Disease
Interventions:   Drug: Efavirenz;   Drug: Rilpivirine
Sponsors:   Indiana University;   Indiana University;   Janssen Services, LLC
Not yet recruiting - verified April 2012

Condition:   Staphylococcus Aureus
Interventions:   Drug: XF-73 in 2% gel;   Other: Placebo in 4% gel;   Drug: XF-73 in 4% gel
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Condition:   Neuroblastoma
Interventions:   Biological: ch14.18 -NCI;   Biological: ch14.18-UTC;   Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Biological: Aldesleukin (IL-2);   Drug: Isotretinoin
Sponsors:   United Therapeutics;   United Therapeutics
Not yet recruiting - verified May 2012

Conditions:   Sarcoma;   Solid Tumors;   Pulmonary Metastases;   Lung Metastases;   Osteosarcomas;   Ewing Sarcoma
Interventions:   Drug: Aerosol IL-2;   Procedure: Symptom Assessment
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Shannon Wilkes Foundation
Not yet recruiting - verified May 2012

Condition:   Pulmonary Artery Hypertension
Intervention:  
Sponsors:   University of Pittsburgh;   University of Pittsburgh
Recruiting - verified April 2012

Condition:   HIV Infections
Interventions:   Biological: HIV-MAG vaccine;   Biological: IL-12 pDNA adjuvant;   Biological: VSV HIV gag vaccine;   Biological: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Conditions:   Cervical Cancer;   Oropharyngeal Cancer;   Vaginal Cancer;   Anal Cancer;   Penile Cancer
Interventions:   Drug: Fluderabine;   Drug: Cycolphosphamide;   Biological: Young TIL;   Biological: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Metastatic Cancer;   Melanoma
Interventions:   Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma
Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Hepatitis C, Chronic
Interventions:   Drug: RO5024048;   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin [Copegus];   Drug: danoprevir;   Drug: ritonavir
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Not yet recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Biological: GEO-D03 DNA vaccine;   Biological: MVA/HIV62B (MVA62B) vaccine;   Biological: Placebo for GEO-D03 DNA;   Biological: Placebo for MVA62B:
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   GeoVax, Inc.
Not yet recruiting - verified May 2012

Condition:   Sexual Transmission of Infection
Interventions:   Behavioral: HIV prevention intervention;   Behavioral: Diet and Nutrition;   Other: Standard of care
Sponsors:   Children's Memorial Hospital;   Children's Memorial Hospital;   National Institute of Mental Health (NIMH)
Recruiting - verified April 2012

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: dolutegravir 50 mg twice daily;   Drug: dolutegravir placebo twice daily;   Drug: Open-label dolutegravir 50mg twice daily
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Shionogi;   GlaxoSmithKline
Recruiting - verified May 2012

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: darunavir/cobicistat/emtricitabine/GS-7340;   Drug: darunavir + cobicistat + emtricitabine/tenofovir df
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Epilepsy
Intervention:  
Sponsors:   Columbia University;   Columbia University;   Epilepsy Foundation;   University of Nebraska
Recruiting - verified March 2012

Condition:   HIV-associated Myelopathy
Interventions:   Drug: Intravenous Immunoglobulin;   Drug: Placebo
Sponsors:   Mount Sinai School of Medicine;   David M. Simpson;   CSL Behring
Recruiting - verified March 2012

Condition:   Substance-Related Disorders
Intervention:   Drug: naltrexone for extended release injectable suspension
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital;   National Institute on Drug Abuse (NIDA);   Alkermes
Recruiting - verified March 2012

Conditions:   HIV;   Patient Compliance
Interventions:   Behavioral: Positive Choices;   Behavioral: Personalized Cognitive Counseling
Sponsors:   Columbia University;   Columbia University;   National Institute of Mental Health (NIMH)
Not yet recruiting - verified March 2012

Condition:   Tuberculosis
Interventions:   Drug: PA-824;   Drug: Efavirenz (EFV);   Drug: Lopinavir/Ritonavir (LPV/r);   Drug: Rifampin (RIF)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Conditions:   Substance-related Disorders;   HIV Risk Behavior
Interventions:   Behavioral: Therapeutic Workplace;   Drug: Methadone
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified March 2012

Conditions:   Inflammation;   Macrophage Infiltration;   Cardiovascular Disease
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Not yet recruiting - verified March 2012

Condition:   HIV-Associated Cognitive Motor Complex
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified December 2011

Condition:   Sexually Transmitted Diseases
Interventions:   Behavioral: Horizons+General Health Promotion (GHP);   Behavioral: Horizons+Motivational Enhancement Therapy (GMET)
Sponsors:   Emory University;   Emory University
Recruiting - verified May 2012

Condition:   HIV
Interventions:   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T
Sponsors:   Sangamo Biosciences;   Sangamo Biosciences
Recruiting - verified April 2012

Condition:   HIV Infections
Interventions:   Drug: Dapivirine Vaginal Film;   Drug: Dapivirine Vaginal Gel
Sponsors:   International Partnership for Microbicides, Inc.;   International Partnership for Microbicides, Inc.
Not yet recruiting - verified March 2012

Condition:   HIV-1 Infection
Intervention:   Drug: Sevelamer carbonate
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   HIV Prevention
Interventions:   Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel;   Drug: Universal HEC Placebo Gel Formulation
Sponsors:   University of Pittsburgh;   Ian McGowan;   National Institute of Allergy and Infectious Diseases (NIAID);   CONRAD
Not yet recruiting - verified April 2012

Condition:   HIV Prevention
Interventions:   Drug: Rectal formulation (RF) of tenofovir 1% gel;   Drug: Vaginal formulation (VF) of tenofovir 1% gel;   Drug: Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel;   Radiation: Radiolabeling of study drugs and semen
Sponsors:   University of Pittsburgh;   Ian McGowan;   National Institute of Allergy and Infectious Diseases (NIAID);   CONRAD
Not yet recruiting - verified April 2012

Condition:   Sexually Transmitted Diseases
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified April 2012

Conditions:   Pregnancy;   Sexually Transmitted Infections
Interventions:   Behavioral: BUtiful. Be yoU! Talented, Informed, Fearless, Uncompromised, Loved;   Behavioral: DIVAS. Diversity, Individuality, Vitality, Activity and Strong.
Sponsors:   Tulane University Health Sciences Center;   Tulane University Health Sciences Center;   Department of Health and Human Services
Not yet recruiting - verified April 2012

Condition:   Plasma Cell Myeloma
Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Procedure: Apheresis
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   HIV Positive
Intervention:  
Sponsors:   Wayne State University;   Wayne State University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012

Conditions:   HIV Positive;   Marijuana Smoking
Intervention:  
Sponsors:   Wayne State University;   Wayne State University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Hydroxychloroquine;   Drug: IL-2
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   Prometheus Laboratories
Recruiting - verified March 2012

Conditions:   Diabetic Neuropathy;   Chemotherapy Induced Neuropathy;   HIV Neuropathy;   Trauma Induced Neuropathy
Intervention:   Drug: Neuron012703 (Medical Food)
Sponsors:   Targeted Medical Pharma;   Targeted Medical Pharma
Not yet recruiting - verified February 2012

Condition:   HIV
Interventions:   Drug: Lisinopril;   Drug: Placebo
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   American Foundation for AIDS Research
Recruiting - verified February 2012

Conditions:   Adolescent HIV Prevention;   Adolescent Unintended Pregnancy
Intervention:   Behavioral: combination HIV prevention package for boys and girls
Sponsors:   New York University;   New York University;   University of Nairobi
Not yet recruiting - verified April 2012

Condition:   HIV
Intervention:   Drug: 3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir
Sponsors:   Fenway Community Health;   Kenneth H. Mayer, MD;   Bristol-Myers Squibb;   Gilead Sciences;   Abbott
Recruiting - verified May 2012

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Intervention:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified April 2012

Condition:   Endothelial Dysfunction
Intervention:   Drug: Telmisartan
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   The Campbell Foundation
Not yet recruiting - verified April 2012

Condition:   Fibrosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Condition:   HIV+
Interventions:   Drug: Vitamin D3;   Drug: Vitamin D3
Sponsors:   University Hospitals of Cleveland;   University Hospitals of Cleveland;   Emory University
Recruiting - verified January 2012

Condition:   Atherosclerosis
Intervention:  
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012

Condition:   Lymphoma
Interventions:   Drug: Lamivudine;   Drug: Tenofovir disoproxil fumarate
Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   GlaxoSmithKline;   Gilead Sciences
Not yet recruiting - verified February 2012

Condition:   AIDS/HIV PROBLEM
Intervention:  
Sponsors:   Gaia Medical Institute;   Gaia Medical Institute;   AIDS Healthcare Foundation
Recruiting - verified January 2012

Conditions:   Sexually Transmitted Infection;   HIV
Interventions:   Behavioral: Tailored Socio-Contextual Intervention;   Behavioral: Standard of Care
Sponsors:   University of Wisconsin, Milwaukee;   University of Wisconsin, Milwaukee;   National Institute of Mental Health (NIMH)
Not yet recruiting - verified January 2012

Condition:   HIV Infection
Interventions:   Drug: Maraviroc;   Drug: Emtricitabine;   Drug: Tenofovir disoproxil fumarate;   Other: Maraviroc placebo;   Other: Emtricitabine placebo;   Other: Tenofovir disoproxil fumarate placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Prevention Trials Network
Not yet recruiting - verified May 2012

Condition:   HIV
Intervention:   Behavioral: Care management
Sponsors:   University of Washington;   University of Washington;   National Institutes of Health (NIH);   National Institute of Mental Health (NIMH);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Not yet recruiting - verified January 2012

Conditions:   Substance Use;   Sexual Risk Behaviors
Interventions:   Behavioral: Risk Reduction Therapy for Adolescents;   Behavioral: Usual services
Sponsors:   Medical University of South Carolina;   Medical University of South Carolina
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:   Drug: Etravirine (ETR)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Condition:   Sarcoma, Kaposi
Intervention:   Drug: Pomalidomide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: Dolutegravir
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Shionogi;   GlaxoSmithKline
Recruiting - verified March 2012

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: NNRTI plus FTC/TDF
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   HIV/AIDS-associated Fatigue
Interventions:   Dietary Supplement: American ginseng (Panax quinquefolius);   Dietary Supplement: Placebo
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Center for Complementary and Alternative Medicine (NCCAM)
Not yet recruiting - verified December 2011

Condition:   Chronic Pain
Intervention:   Behavioral: Therapeutic Education System (TES) for chronic pain
Sponsors:   National Development and Research Institutes, Inc.;   National Development and Research Institutes, Inc.;   National Institute on Drug Abuse (NIDA);   Beth Israel Medical Center
Not yet recruiting - verified December 2011

Condition:   Sexual Transmission of Infection
Interventions:   Biological: Gardasil Vaccine;   Biological: Placebo Vaccine
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Merck
Not yet recruiting - verified May 2012

Condition:   HIV-1 Infection
Interventions:   Drug: BMS-986001;   Drug: BMS-986001;   Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified December 2011

Conditions:   Mestatic Melanoma;   Skin Cancer
Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions:   Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC);   Biological: Test, Treat, Retain(TTR) only
Sponsors:   RTI International;   RTI International;   University of North Carolina, Chapel Hill
Not yet recruiting - verified December 2011

Condition:   Substance Abuse
Intervention:   Other: STaRS
Sponsors:   Polaris Health Directions;   Polaris Health Directions;   University of Massachusetts, Worcester
Not yet recruiting - verified December 2011

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Tobacco Cessation;   HIV;   AIDS
Interventions:   Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Gay Men’s Health Crisis;   The City College of New York;   AIDS Center of Queens County;   Bronx AIDS Services;   Bronx Community Pride Center;   Brooklyn AIDS Task Force;   Fortune Society;   Harlem United Community AIDS Center;   Iris House;   North Jersey Community Research Initiative
Recruiting - verified February 2012

Condition:   HIV Infections
Interventions:   Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   HIV;   PCP;   Toxoplasmosis
Interventions:   Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified October 2011

Conditions:   Substance Abuse;   HIV
Interventions:   Behavioral: Computer-facilitated HIV intervention;   Behavioral: Attention Control
Sponsors:   Treatment Research Institute;   Treatment Research Institute;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified November 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: danoprevir;   Drug: ritonavir;   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   Cervical Cancer
Interventions:   Drug: Nelfinavir;   Drug: Cisplatin;   Radiation: Pelvic External Beam Radiation Therapy;   Radiation: Brachytherapy;   Procedure: Pharmacokinetic Sampling;   Procedure: Cervical Biopsy;   Procedure: Pelvic Examination;   Procedure: Pap Smear;   Procedure: Audiogram;   Procedure: Proctoscopy;   Procedure: Cytoscopy;   Procedure: Renal Ultrasound;   Procedure: CT Scan;   Procedure: Whole Body PET/CT Scan
Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
Not yet recruiting - verified December 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   Tobira Therapeutics, Inc.
Recruiting - verified January 2012

Condition:   HIV-1 Infection
Interventions:   Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate;   Drug: Pravastatin sodium
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Condition:   HIV Infection
Interventions:   Dietary Supplement: Probiotics;   Dietary Supplement: Placebo
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Not yet recruiting - verified November 2011

Condition:   Hepatitis C, Genotype 1
Interventions:   Drug: BMS-790052 (Daclatasvir);   Drug: Ribavirin;   Drug: Peg-Interferon alfa 2a
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Condition:   Hepatitis C
Interventions:   Drug: Telaprevir;   Drug: Ribavirin;   Biological: peginterferon alfa-2a
Sponsors:   Vertex Pharmaceuticals Incorporated;   Vertex Pharmaceuticals Incorporated
Recruiting - verified May 2012

Conditions:   Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions:   Biological: recombinant interferon gamma;   Biological: aldesleukin;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Biological: NY-ESO-1-specific T lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Biological: Quadrivalent HPV Vaccine;   Biological: Placebo Vaccine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   Human Immunodeficiency Virus
Intervention:   Drug: Atripla (EFV/TDF/FTC); boosted darunavir & tenofovir/FTC; boosted atazanavir & tenofovir/FTC; raltegravir & tenofovir/FTC
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011

Condition:   Human Immunodeficiency Virus
Intervention:   Procedure: Genital and rectal swabbing
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   Hodgkin Disease;   Hodgkin Lymphoma
Interventions:   Drug: Filgrastim;   Drug: Plerixafor;   Drug: Yttrium-Daclizumab (CHX-A Daclizumab);   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Ca(2+)-DTPA
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   HIV
Intervention:   Behavioral: Peer Navigator Intervention
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles
Not yet recruiting - verified October 2011

Condition:   Healthy
Intervention:   Drug: dolutegravir
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   GlaxoSmithKline
Recruiting - verified December 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Recruiting - verified November 2011

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   GlaxoSmithKline
Recruiting - verified February 2012

Conditions:   HIV;   AIDS
Intervention:   Behavioral: Video or In-Person Presentation
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital
Recruiting - verified August 2011

Condition:   HIV-1 Infection
Intervention:   Drug: Rifaximin
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   Women's Health;   HIV Infection;   Genital Diseases, Female
Intervention:  
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver
Recruiting - verified October 2011

Condition:   Amphetamine-Related Disorders
Interventions:   Drug: extended-release naltrexone;   Drug: Placebo
Sponsors:   National Institute on Drug Abuse (NIDA);   National Institute on Drug Abuse (NIDA);   Alkermes
Not yet recruiting - verified October 2011

Conditions:   Hepatitis;   HIV/AIDS
Interventions:   Drug: Boceprevir;   Drug: Peg-Interferon-alfa 2B;   Drug: Ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Condition:   Bacterial Vaginosis
Interventions:   Dietary Supplement: Vitamin D3 (cholecalciferol);   Dietary Supplement: Placebo
Sponsors:   Ohio State University;   Ohio State University
Recruiting - verified October 2011

Conditions:   HIV Infections;   Central Nervous System Neoplasms;   Neurofibromatosis 1
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   HIV Infection;   Hepatitis C
Intervention:   Behavioral: Contigent voucher incentive (CVI)
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2011

Condition:   Hepatitis C, Chronic
Intervention:  
Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
Recruiting - verified May 2012

Conditions:   Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:  
Sponsors:   G & W Laboratories Inc.;   G & W Laboratories Inc.;   Alquest;   SMART Biotech Ltd
Recruiting - verified October 2011

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: Cobicistat;   Drug: Darunavir
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified October 2011

Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
Interventions:   Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   H5N1 Influenza
Interventions:   Biological: Ad4-H5-VTN vaccination-tonsillar route;   Biological: Ad4-H5-vaccination-oral route
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   HIV Infections
Interventions:   Biological: VSV-Indiana HIV gag vaccine;   Biological: Placebo injection (normal saline)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Gonorrhea;   Chlamydia;   Trichomoniasis;   Syphilis;   HIV Infections
Intervention:   Behavioral: Intervention
Sponsors:   University of Kentucky;   University of Kentucky;   National Institute of Mental Health (NIMH)
Not yet recruiting - verified September 2011

Conditions:   Castleman Disease;   Castleman's Disease;   Giant Lymph Node Hyperplasia
Interventions:   Drug: Zidovudine;   Drug: Tocilizumab;   Drug: Valganciclovir
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Acute HIV Infection
Intervention:   Other: Nucleic Acid Amplification Testing
Sponsors:   University of California, San Diego;   University of California, San Diego;   National Institutes of Health (NIH)
Recruiting - verified September 2011

Condition:   HIV-infection/Aids
Interventions:   Dietary Supplement: Vitamin D3;   Dietary Supplement: Placebo
Sponsors:   Children's Hospital of Philadelphia;   Children's Hospital of Philadelphia;   National Institutes of Health (NIH);   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified November 2011

Condition:   Hepatitis C Virus
Interventions:   Drug: ABT-450/r;   Drug: ABT-267;   Drug: ribavirin
Sponsors:   Abbott;   Abbott
Recruiting - verified February 2012

Condition:   Herpes Simplex Type II
Interventions:   Drug: Tenofovir;   Drug: placebo gel;   Drug: tenofovir disoproxil fumarate (TDF);   Drug: placebo tablets
Sponsors:   University of Washington;   University of Washington;   CONRAD;   Gilead Sciences
Recruiting - verified March 2012

Condition:   HIV Infection
Intervention:   Drug: Polyphenon E
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified September 2011

Condition:   Opiate Dependence
Interventions:   Other: Patient-Centered Methadone Treatment;   Other: Methadone Treatment as usual
Sponsors:   Friends Research Institute, Inc.;   Friends Research Institute, Inc.
Recruiting - verified September 2011

Condition:   HIV Infections
Interventions:   Biological: HIVAX;   Biological: saline solution;   Biological: HIVAX;   Biological: Saline solution
Sponsors:   GeneCure Biotechnologies;   GeneCure Biotechnologies
Recruiting - verified September 2011

Conditions:   HIV;   Risk Reduction Behavior
Intervention:   Behavioral: MILE intervention
Sponsors:   University of Southern California;   University of Southern California;   Charles Drew University of Medicine and Science;   Centers for Disease Control and Prevention
Recruiting - verified August 2011

Condition:   HIV
Interventions:   Drug: Twice-daily Darunavir/ritonavir;   Drug: Once-daily Darunavir/ritonavir
Sponsors:   Ruth M. Rothstein CORE Center;   Ruth M. Rothstein CORE Center;   Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Not yet recruiting - verified January 2012

Conditions:   Hepatitis C;   HIV
Intervention:   Drug: boceprevir; etravirine
Sponsors:   University of Colorado, Denver;   University of Colorado, Denver
Recruiting - verified August 2011

Condition:   Pulmonary Arterial Hypertension
Intervention:   Device: Ventripoint Medical System
Sponsors:   VentriPoint Diagnostics Ltd.;   VentriPoint Diagnostics Ltd.
Recruiting - verified April 2012

Conditions:   HIV Infection;   Hepatitis C
Intervention:  
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011

Conditions:   Contraceptive Usage;   Opioid Dependence
Interventions:   Behavioral: Contraceptive management program;   Other: Usual care
Sponsors:   University of Vermont;   University of Vermont
Recruiting - verified December 2011

Condition:   HIV Prevention
Interventions:   Behavioral: Integrated treatment program;   Behavioral: Treatment as Usual
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital;   National Institute of Mental Health (NIMH)
Recruiting - verified August 2011

Conditions:   KSHV Inflammatory Cytokine Syndrome (KICS);   KSHV;   HHV-8
Interventions:   Drug: Zidovudine/Valgancyclovir;   Drug: Rituximab/Liposoma Doxorubicin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   HIV;   AIDS;   Peripheral Neuropathy;   Pain;   Sleep
Interventions:   Device: Splinting application to the lower extremities;   Device: Splint liner application
Sponsors:   Texas Woman's University;   Texas Woman's University;   Harris County Hospital District;   DJO Incorporated
Recruiting - verified March 2012

Conditions:   HIV;   Drug Use Disorders
Interventions:   Behavioral: HEART to HAART;   Behavioral: adherence counseling with the addition of smartphone control
Sponsors:   University of Maryland;   University of Maryland;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified August 2011

Condition:   Type 1 Diabetes Mellitus
Intervention:   Drug: Atazanavir
Sponsors:   Brigham and Women's Hospital;   Brigham and Women's Hospital;   National Institutes of Health (NIH)
Not yet recruiting - verified August 2011

Condition:   HIV Prevention
Interventions:   Drug: Tenofovir 1% vaginal gel;   Drug: Depo-medroxyprogesterone acetate (DMPA);   Drug: Oral contraceptive: LNG 150 mcg and EE 30 mcg
Sponsors:   CONRAD;   CONRAD
Recruiting - verified May 2012

Condition:   Vitamin D Deficiency
Intervention:  
Sponsors:   University Hospitals of Cleveland;   University Hospitals of Cleveland;   Emory-Children's Center
Recruiting - verified February 2012

Conditions:   Leukemia;   Lymphoma;   HIV
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI);   Drug: Fludarabine;   Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Condition:   Opiate Dependence
Intervention:   Behavioral: employment based reinforcement
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2010

Conditions:   Liver Diseases, Alcoholic;   Alcoholism;   HIV;   Hepatitis C
Interventions:   Other: Integrated Stepped Care (ISC);   Other: Treatment as Usual
Sponsors:   Yale University;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   Department of Veterans Affairs
Not yet recruiting - verified August 2011

Condition:   The Focus of the Study is the Treatment and Retention in Treatment for HIV+ ex Inmates.
Intervention:   Behavioral: Peer Navigator
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles
Not yet recruiting - verified July 2011

Condition:   HIV-infection
Intervention:   Drug: Angiotensin II Infusion
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified February 2012

Condition:   HIV
Interventions:   Drug: Eplerenone and lifestyle;   Other: placebo and lifestyle
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified February 2012

Conditions:   Tuberculosis;   HIV Infections
Interventions:   Drug: Rifapentine (RPT);   Drug: Isoniazid (INH);   Dietary Supplement: Pyridoxine (Vitamin B6)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified May 2012

Condition:   Myeloma
Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Procedure: Apheresis;   Drug: Melphalan;   Procedure: Stem cell re-infusion;   Drug: Basiliximab;   Device: CliniMACS CD25 microbeads and cell sorter
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified January 2012

Condition:   HIV-1 Infection
Interventions:   Drug: Atripla;   Drug: Calcium Carbonate;   Drug: Vitamin D3;   Drug: Placebo for calcium carbonate;   Drug: Placebo for vitamin D3
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   HIV/AIDS
Intervention:   Behavioral: cognitive-behavioral therapy
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles;   Yale University;   Harbor Medical Inc.
Not yet recruiting - verified July 2011

Condition:   HIV-1 Infection
Interventions:   Drug: Darunavir;   Drug: Ritonavir;   Drug: Tenofovir disoproxil fumarate;   Drug: Emtricitabine;   Drug: Placebo for Tenofovir disoproxil fumarate;   Drug: Placebo for Maraviroc
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified September 2011

Condition:   Hepatitis C, Chronic
Interventions:   Drug: BI201335;   Drug: BI201335 24W;   Drug: PegIFN/RBV;   Drug: PegIFN/RBV
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012

Condition:   Acquired Immunodeficiency Syndrome
Intervention:  
Sponsors:   Stanford University;   Stanford University
Recruiting - verified July 2011

Condition:   Melanoma
Interventions:   Drug: Ipilimumab;   Drug: Temozolomide;   Drug: Cisplatin;   Drug: Interferon Alfa-2b;   Drug: Interleukin-2
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Not yet recruiting - verified February 2012

Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: etoposide;   Procedure: leukapheresis
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   HIV;   Sexually Transmitted Infections
Interventions:   Behavioral: Connect 'n Unite;   Behavioral: Wellness Promotion
Sponsors:   Columbia University;   Columbia University;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified January 2012

Condition:   HIV Infected
Intervention:   Drug: Tenofovir, Emtricitabine, Atazanavir, Ritonavir
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   Correct and Consistent Condom Use.
Intervention:   Behavioral: Homework Intervention Strategy
Sponsors:   Indiana University;   Indiana University
Recruiting - verified February 2012

Conditions:   Nicotine Dependence;   Symptoms of Anxiety;   HIV
Intervention:   Behavioral: Integrated cognitive-behavioral therapy for smoking cessation and anxiety
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Southern Methodist University;   University of Houston
Recruiting - verified July 2011

Conditions:   Sexual Risk Behavior;   Childhood Sexual Abuse;   Stress Disorders, Post-Traumatic
Interventions:   Behavioral: Cognitive Processing Therapy for Sexual Risk;   Behavioral: Supportive Psychotherapy;   Behavioral: Sexual Risk Reduction Intervention
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Fenway Community Health;   University of Miami
Recruiting - verified March 2012

Condition:   Healthy Volunteers
Interventions:   Drug: GLA-AF;   Drug: GLA-SE;   Other: Squalene
Sponsors:   Rockefeller University;   Rockefeller University;   IDRI Corporation;   Immune Design
Recruiting - verified February 2012

Conditions:   Drug Use;   HIV;   Hepatitis C
Intervention:   Behavioral: Brief motivational intervention
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital;   National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011

Conditions:   HIV Negative;   Adaptive Immunity;   Innate Immunity
Interventions:   Biological: VRC-HIVDNA016-00-VP;   Biological: VRC-HIVADV014-00-VP
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified June 2011

Condition:   Vaginosis, Bacterial
Intervention:   Drug: Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring
Sponsors:   Eastern Virginia Medical School;   Eastern Virginia Medical School;   Merck
Recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Drug: Zoledronic Acid;   Biological: Aldesleukin
Sponsors:   University of Alabama at Birmingham;   Joseph Pressey, MD
Recruiting - verified December 2011

Condition:   HIV
Interventions:   Behavioral: Standard Referral;   Behavioral: Project Bridge
Sponsors:   RTI International;   RTI International;   National Institute of Mental Health (NIMH)
Recruiting - verified April 2012

Condition:   Human Immunodeficiency Virus-1
Interventions:   Drug: BMS-663068;   Drug: BMS-663068;   Drug: BMS-663068;   Drug: BMS-663068;   Drug: Raltegravir;   Drug: Raltegravir;   Drug: Tenofovir;   Drug: Tenofovir;   Drug: Ritonavir;   Drug: Atazanavir
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Conditions:   Leukemia;   Chronic Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Procedure: NK cell infusion:;   Drug: Interleukin-2;   Drug: Anti-Thymocyte Globulin;   Procedure: Allogeneic related Stem Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Sexual Risk;   Substance Use
Intervention:   Other: Behavioral: HIV prevention intervention
Sponsors:   Hunter College;   Hunter College
Not yet recruiting - verified June 2011

Condition:   Influenza, Human
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Human Immunodeficiency Virus;   Acquired Immunodeficiency Syndrome;   Opiate Addiction;   Drug Dependence
Intervention:   Drug: Buprenorphine/naloxone
Sponsors:   Yale University;   Yale University;   George Mason University;   Howard University
Recruiting - verified April 2012

Condition:   HIV
Interventions:   Behavioral: Monetary Incentive;   Behavioral: Questionnaire Timing;   Behavioral: HIV Test Offering
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Institutes of Health (NIH);   National Institute on Aging (NIA)
Recruiting - verified February 2012

Conditions:   Tuberculosis, Pulmonary;   Mycobacterium Tuberculous;   Antitubercular Agents;   Tuberculosis, Mulutidrug-Resistant;   Extensively Drug-Resistant;   Extensibely Drug-Resistant Tuberculosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Substance Abuse;   HIV Risk;   Criminogenic Thinking;   Shame;   Guilt;   Empathy
Interventions:   Behavioral: MI plus IOC group intervention;   Behavioral: Motivational Interview only
Sponsors:   George Mason University;   George Mason University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011

Conditions:   Impulsive Behavior;   Substance Abuse;   HIV Risk Behavior;   Anxiety;   Depression;   Criminogenic Thinking
Interventions:   Behavioral: REVAMP;   Behavioral: TAU
Sponsors:   George Mason University;   George Mason University
Recruiting - verified June 2011

Conditions:   Substance Abuse;   HIV Risk;   Shame;   Guilt;   Empathy;   Criminogenic Thinking
Interventions:   Behavioral: Impact of Crime Modules;   Behavioral: TAU
Sponsors:   George Mason University;   George Mason University;   National Institute on Drug Abuse (NIDA)
Not yet recruiting - verified June 2011

Conditions:   HIV;   Opiate Dependence
Interventions:   Behavioral: Abstinence-reinforcing contingency management intervention;   Behavioral: Performance Feedback intervention
Sponsors:   Albert Einstein College of Medicine of Yeshiva University;   Albert Einstein College of Medicine of Yeshiva University;   National Institute on Drug Abuse (NIDA);   The City University of New York
Not yet recruiting - verified June 2011

Conditions:   Bone Mineral Density;   Bone;   Osteoporosis
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham
Recruiting - verified January 2012

Conditions:   Unsafe Sex;   Risk Reduction
Interventions:   Behavioral: PROJECT POWER;   Behavioral: Power Health
Sponsors:   Nova Southeastern University;   Nova Southeastern University;   John H. Stroger Hospital
Recruiting - verified November 2011

Condition:   HIV
Interventions:   Drug: Vitamin D3;   Drug: Placebo
Sponsors:   Columbia University;   Columbia University;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Conditions:   Human Immunodeficiency Virus (HIV);   Self-efficacy;   Self-esteem
Intervention:   Behavioral: Ipod video
Sponsors:   Duke University;   Duke University;   National Institute of Nursing Research (NINR)
Not yet recruiting - verified July 2011

Conditions:   Depression;   HIV
Intervention:   Other: Measurement-Based Care collaborative depression management
Sponsors:   Duke University;   Duke University;   National Institute of Mental Health (NIMH);   University of North Carolina, Chapel Hill;   University of Alabama at Birmingham
Recruiting - verified June 2011

Conditions:   Cardiovascular Diseases;   Hyperlipidemia;   Obesity
Interventions:   Behavioral: Physical Activity Group;   Other: Standard Care Group
Sponsors:   University of South Carolina;   University of South Carolina;   National Institute of Nursing Research (NINR)
Recruiting - verified February 2012

Condition:   HIV Prevention
Intervention:   Drug: Tenofovir 1% vaginal gel
Sponsors:   CONRAD;   CONRAD
Recruiting - verified March 2012

Condition:   Chemotherapy-Induced Nausea and Vomiting
Interventions:   Drug: Netupitant and Palonosetron;   Drug: Aprepitant and Palonosetron
Sponsors:   Helsinn Healthcare SA;   Helsinn Healthcare SA;   Parexel
Recruiting - verified December 2011

Condition:   HIV
Intervention:   Behavioral: Project Bridge
Sponsors:   Friends Research Institute, Inc.;   Friends Research Institute, Inc.;   National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2011

Condition:   Leukemia, Lymphocytic, Chronic, B-Cell
Intervention:   Drug: Lenalidomide + Plerixafor (+ Rituximab)
Sponsors:   Duke University;   Duke University;   Celgene Corporation;   Genzyme
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Drug: Dapivirine Vaginal Ring;   Drug: Maraviroc Vaginal Ring;   Other: Placebo Vaginal Ring;   Drug: Dapivirine-Maraviroc Vaginal Ring
Sponsors:   International Partnership for Microbicides, Inc.;   International Partnership for Microbicides, Inc.
Recruiting - verified November 2011

Conditions:   HIV Infection;   Substance Abuse
Interventions:   Behavioral: Trans-theoretical Process of Change Model-self;   Behavioral: Trans-theoretical Process of Change Model - interviewer
Sponsors:   Nova Southeastern University;   Nova Southeastern University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Alcohol Abuse
Interventions:   Behavioral: CBI;   Behavioral: TBI
Sponsors:   University of Michigan;   University of Michigan;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012

Condition:   Hepatitis B
Interventions:   Drug: Tenofovir;   Drug: Combination of peginterferon alfa 2a and tenofovir
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   University of Pittsburgh
Not yet recruiting - verified February 2012

Conditions:   Methamphetamine Dependence;   Substance Abuse;   Methamphetamine Abuse
Interventions:   Drug: Varenicline;   Drug: Placebo
Sponsors:   University of California, Los Angeles;   University of California, Los Angeles
Recruiting - verified March 2012

Condition:   Human Immunodeficiency Virus (HIV) Infection
Intervention:   Drug: Etravirine
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Medication Adherence
Interventions:   Behavioral: Adherence Counseling;   Behavioral: General Health Counseling;   Behavioral: Text Messages
Sponsors:   University of Connecticut;   University of Connecticut;   National Institute of Nursing Research (NINR)
Recruiting - verified May 2012

Conditions:   Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions:   Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF;   Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Conditions:   Alcohol Consumption;   Unsafe Sex
Interventions:   Behavioral: Brief Motivational Intervention (BMI);   Behavioral: Brief Advice
Sponsors:   Brown University;   Brown University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA);   Memorial Hospital of Rhode Island;   Kent Hospital
Recruiting - verified November 2011

Conditions:   Hepatitis;   HIV;   Liver Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC);   Washington DC Veterans Affairs Medical Center
Recruiting - verified February 2012

Condition:   HIV
Intervention:   Behavioral: Treatment Advocacy
Sponsors:   Children's Hospital Boston;   Children's Hospital Boston;   National Institute of Mental Health (NIMH)
Recruiting - verified May 2012

Condition:   HIV-1
Interventions:   Drug: Maraviroc;   Drug: Emtricitabine/tenofovir
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Pfizer
Recruiting - verified May 2012

Condition:   Diabetic Ulcer
Intervention:   Drug: AMD3100 injection + rhPDGF-BB topical
Sponsors:   New York University School of Medicine;   New York University School of Medicine;   National Institutes of Health (NIH);   Genzyme
Not yet recruiting - verified May 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
Recruiting - verified November 2011

Condition:   HIV-1 Infection
Interventions:   Drug: Cenicriviroc 100 mg;   Drug: Cenicriviroc 200 mg + Truvada;   Drug: Sustiva + Truvada
Sponsors:   Tobira Therapeutics, Inc.;   Tobira Therapeutics, Inc.
Recruiting - verified October 2011

Condition:   HIV Disease
Interventions:   Drug: HAART regimen;   Drug: 3TC or FTC monotherapy
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012

Condition:   HIV
Intervention:  
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified April 2012

Condition:   HIV
Interventions:   Drug: Atazanavir Sulphate;   Drug: Ritonavir
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified April 2012

Conditions:   HIV;   Hepatitis C;   HIV and Hepatitis C Coinfection
Intervention:  
Sponsors:   University of Cincinnati;   University of Cincinnati;   Merck
Recruiting - verified January 2012

Condition:   HIV, Combination Therapy
Interventions:   Drug: Atazanavir;   Drug: Ritonavir (heat-stable);   Drug: Raltegravir;   Drug: Tenofovir/Emtricitabine
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Microbicide Delivery System Acceptability
Intervention:  
Sponsors:   The Miriam Hospital;   The Miriam Hospital;   ImQuest Pharmaceuticals, Inc.;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   HIV Infection
Intervention:   Behavioral: Positive STEPS
Sponsors:   Fenway Community Health;   Fenway Community Health;   Children's Hospital Boston;   Massachusetts General Hospital;   Harvard University
Recruiting - verified April 2011

Condition:   HIV Lipodystrophy
Interventions:   Drug: mecasermin;   Drug: Placebo control
Sponsors:   University of Texas Southwestern Medical Center;   University of Texas Southwestern Medical Center
Recruiting - verified March 2012

Condition:   Acute Myeloid Leukemia
Interventions:   Drug: plerixafor;   Drug: decitabine
Sponsors:   Weill Medical College of Cornell University;   Weill Medical College of Cornell University;   Genzyme
Recruiting - verified June 2011

Conditions:   Recurrent Melanoma;   Stage IV Melanoma
Interventions:   Drug: cyclophosphamide;   Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Other: laboratory biomarker analysis;   Other: immunologic technique;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Biological: therapeutic autologous lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Infection, Human Immunodeficiency Virus
Intervention:   Drug: dolutegravir
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Shionogi;   GlaxoSmithKline
Recruiting - verified February 2012

Conditions:   Non-Hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Drug: Plerixafor;   Drug: Filgrastim
Sponsors:   University of Florida;   University of Florida
Recruiting - verified March 2012

Conditions:   Hazardous Drinking;   HIV
Intervention:   Behavioral: Brief alcohol intervention
Sponsors:   Brown University;   Brown University
Recruiting - verified October 2011

Condition:   HIV
Intervention:   Drug: Raltegravir
Sponsors:   University of Washington;   University of Washington;   Merck
Recruiting - verified October 2011

Condition:   HIV/AIDS
Interventions:   Behavioral: Family-Based HIV prevention;   Other: Adolescent Only Health Promotion
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital
Recruiting - verified July 2011

Condition:   Tuberculosis
Interventions:   Drug: TMC207;   Drug: Rifampin;   Drug: Rifabutin
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Conditions:   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Precancerous Condition;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: veliparib;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   Memorial Sloan-Kettering Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   High Grade Glioma: Glioblastoma (GBM);   High Grade Glioma: Gliosarcoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions:   Drug: Plerixafor;   Drug: Plerixafor;   Drug: Bevacizumab;   Drug: Plerixafor;   Procedure: Surgery
Sponsors:   Dana-Farber Cancer Institute;   Patrick Y. Wen, MD;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Massachusetts General Hospital;   Genzyme
Recruiting - verified February 2012

Conditions:   HIV Coinfection;   Hepatitis C;   Hepatitis B;   Hepatotoxicity
Interventions:   Drug: Maraviroc;   Drug: Placebo
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Pfizer
Recruiting - verified May 2012

Condition:   HIV Infection
Intervention:   Behavioral: Community Mobilization
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Recruiting - verified October 2011

Condition:   Acquired Immunodeficiency Syndrome
Intervention:  
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified October 2011

Condition:   Anal Cancer
Interventions:   Drug: Tempol;   Drug: 5-Fluorouracil;   Drug: Mitomycin-C;   Procedure: Radiation Therapy
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   HIV-1 Infection
Intervention:   Drug: Vorinostat
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   National Institutes of Health (NIH);   Merck;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   HIV;   Hepatitis C;   Hepatitis B;   Syphilis
Interventions:   Device: Rapid tests for HIV, HCV, HBV, and syphilis;   Device: HIV/HCV;   Device: HIV/syphilis;   Device: HIV only
Sponsors:   California State University, Long Beach;   California State University, Long Beach;   National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012

Condition:   Behavioral Disorders Due to Psychoactive Substance Use
Interventions:   Behavioral: HealthCall and Motivational Interviewing;   Behavioral: Motivational Interviewing (MI);   Behavioral: HIV/AIDS health education
Sponsors:   Research Foundation for Mental Hygiene;   Research Foundation for Mental Hygiene
Recruiting - verified March 2010

Conditions:   HIV;   Depression;   Drug Use
Interventions:   Behavioral: Workshop;   Behavioral: Workshop control
Sponsors:   Johns Hopkins Bloomberg School of Public Health;   Johns Hopkins Bloomberg School of Public Health;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011

Conditions:   Metastatic Melanoma;   Skin Cancer
Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Fanconi Anemia
Interventions:   Biological: filgrastim;   Drug: plerixafor;   Procedure: leukapheresis;   Biological: genetically engineered lymphocyte therapy;   Other: laboratory biomarker analysis;   Genetic: polymerase chain reaction
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions:   Procedure: peripheral blood stem cell transplantation (PBSCT);   Biological: filgrastim;   Genetic: polymerase chain reaction;   Biological: rituximab;   Biological: genetically engineered lymphocyte therapy;   Other: laboratory biomarker analysis;   Drug: plerixafor;   Procedure: autologous hematopoietic stem cell transplantation
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   HIV Infection;   Cardiovascular Disease;   Inflammation
Intervention:  
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   GlaxoSmithKline
Recruiting - verified November 2011

Conditions:   HIV;   Medication Adherence;   Substance Dependence
Intervention:   Behavioral: Spiritual Self-Schema Therapy
Sponsors:   Hunter College;   Hunter College;   Fordham University
Recruiting - verified February 2011

Conditions:   Relapsed/Refractory AML;   Relapsed/Refractory ALL;   Secondary AML/MDS;   Acute Leukemia of Ambiguous Lineage;   AML;   ALL
Intervention:   Drug: Plerixafor Dose Escalation
Sponsors:   Emory University;   Emory University;   Children's Healthcare of Atlanta;   Pediatric Oncology Experimental Therapeutics Investigation Consortium
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Drug: GSK1349572 tablet formulation;   Drug: GSK1349572 pediatric formulation
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   HIV-1 Infection
Intervention:   Drug: depo-medroxyprogesterone acetate
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   HIV Infection
Intervention:   Drug: Interferon Alpha 2b
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   HIV-associated Co-morbidities
Interventions:   Dietary Supplement: conventional vitamin D treatment versus a tiered/titrated dosing strategy;   Drug: tiered/titrated vitamin D treatment
Sponsors:   Mount Sinai School of Medicine;   Andrea D. Branch;   National Institute on Drug Abuse (NIDA)
Recruiting - verified January 2012

Condition:   HIV
Interventions:   Drug: Raltegravir;   Drug: Efavirenz
Sponsors:   University of California, San Diego;   University of California, San Diego;   Merck
Recruiting - verified January 2012

Condition:   Refractory Multiple Myeloma
Interventions:   Drug: plerixafor;   Biological: filgrastim
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Contraception
Intervention:   Drug: one of 5 products
Sponsors:   FHI 360;   FHI 360;   National Institutes of Health (NIH)
Recruiting - verified April 2012

Condition:   Healthy Volunteers
Intervention:   Drug: Poly ICLC
Sponsors:   Rockefeller University;   Rockefeller University
Recruiting - verified January 2012

Condition:   HIV Infection
Intervention:   Drug: Lopinavir/ritonavir (LPV/r)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Abbott
Recruiting - verified May 2012

Condition:   Transplantation Infection
Interventions:   Drug: Cidofovir;   Other: No Cidofovir
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   HIV Infection;   Hepatitis C
Interventions:   Drug: Anti-HIV Agents;   Drug: raltegravir;   Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011

Condition:   AIDS
Interventions:   Behavioral: FAmily CEntered (FACE) ACP;   Behavioral: Healthy Living Control
Sponsors:   Children's Research Institute;   Children's Research Institute;   St. Jude Children's Research Hospital;   Johns Hopkins University;   University of Miami
Recruiting - verified February 2012

Conditions:   HIV;   Sexually Transmitted Diseases
Intervention:   Behavioral: It's Your Game Tech
Sponsors:   The University of Texas Health Science Center, Houston;   The University of Texas Health Science Center, Houston;   National Institute of Mental Health (NIMH)
Recruiting - verified March 2012

Condition:   Failure of Bone Marrow Graft
Intervention:   Drug: Plerixafor
Sponsors:   Duke University;   Duke University;   Genzyme
Recruiting - verified February 2012

Condition:   Chronic Hepatitis B
Interventions:   Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a;   Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a;   Drug: Tenofovir Disoproxil Fumarate;   Drug: Peginterferon α-2a
Sponsors:   Gilead Sciences;   Gilead Sciences
Recruiting - verified March 2012

Condition:   HIV Infections
Interventions:   Biological: Profectus HIV MAG pDNA vaccine;   Biological: IL-12;   Other: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   HIV-1 Infection
Intervention:   Drug: Rilpivirine
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified May 2012

Condition:   Healthy
Intervention:   Drug: Non-medicated Intravaginal Ring
Sponsors:   Population Council;   Population Council;   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Mental Health (NIMH);   Microbicide Trials Network
Recruiting - verified May 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified June 2011

Condition:   HIV Dementia
Intervention:   Drug: Atorvastatin
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   HIV;   HIV Lipodystrophy
Interventions:   Drug: tesamorelin;   Drug: placebo
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified April 2012

Condition:   HIV Infections
Interventions:   Biological: PENNVAX-G DNA Vaccine;   Biological: MVA-CMDR Vaccine;   Biological: Placebo PENNVAX-G Vaccine;   Biological: Placebo MVA-CMDR Vaccine
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Alcohol Abuse;   Alcohol Dependence
Interventions:   Drug: ondansetron;   Drug: placebo ondansetron;   Drug: Ondansetron
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified February 2012

Condition:   Smoking
Interventions:   Dietary Supplement: Broccoli sprout homogenate;   Dietary Supplement: Alfalfa sprout homogenate
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012

Condition:   HIV-1
Interventions:   Drug: lersivirine;   Drug: lersivirine;   Drug: efavirenz;   Drug: lersivirine;   Drug: lersivirine;   Drug: etravirine
Sponsors:   Pfizer;   Pfizer;   ViiV Healthcare
Recruiting - verified May 2012

Conditions:   Crystal Methamphetamine Abuse;   Crystal Methamphetamine Dependence
Interventions:   Behavioral: Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR);   Behavioral: Information, Motivation, Behavioral skills change approach to sexual risk reduction
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Fenway Community Health
Recruiting - verified May 2012

Condition:   HIV Infection
Interventions:   Behavioral: Bruthas Project;   Behavioral: Standard HIV Testing and Counseling
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Institute of Mental Health (NIMH)
Recruiting - verified January 2012

Condition:   Melanoma (Skin)
Interventions:   Biological: aflibercept;   Biological: aldesleukin
Sponsors:   National Cancer Institute (NCI);   Beckman Research Institute;   National Cancer Institute (NCI)
Recruiting - verified July 2011

Conditions:   Anal Cancer;   Breast Cancer;   Esophageal Cancer;   Gastric Cancer;   Head and Neck Cancer;   Lung Cancer;   Nonneoplastic Condition;   Ovarian Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Drug: vorinostat;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Glioblastoma Multiforme;   Gliosarcoma;   Anaplastic Astrocytoma;   Anaplastic Oligodendroglioma;   Anaplastic Mixed Oligoastrocytoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Conditions:   HIV;   AIDS;   Opioid Dependence;   Drug Dependence
Intervention:   Drug: Depot Naltrexone
Sponsors:   Yale University;   Yale University;   Baystate Medical Center
Recruiting - verified August 2011

Conditions:   HIV;   Alcoholism
Intervention:   Drug: Naltrexone
Sponsors:   University of Florida;   University of Florida;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified April 2012

Condition:   HIV-1 Infection
Interventions:   Drug: atorvastatin;   Drug: atorvastatin
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Pfizer
Recruiting - verified September 2011

Condition:   Laboratory Procedure Development and Validation
Intervention:   Other: no intervention
Sponsors:   University of Pittsburgh;   Sharon Hillier;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Conditions:   HIV;   AIDS;   Substance Use Disorders
Intervention:   Behavioral: Resilient Affective Processing Therapy (RAPT)
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified March 2012

Condition:   Human Immunodeficiency Virus
Intervention:   Drug: emtricitabine/tenofovir disoproxil fumarate
Sponsors:   Henry Ford Health System;   Henry Ford Health System
Recruiting - verified June 2011

Condition:   ADHD
Intervention:  
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Recruiting - verified May 2012

Conditions:   HIV;   Pregnancy
Intervention:   Other: Vaginal lavage specimen
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified December 2011

Conditions:   Bacterial Vaginosis;   Trichomoniasis;   Candidiasis
Interventions:   Drug: Placebo;   Drug: Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   Medication Adherence
Interventions:   Device: Beeper;   Device: ARemind
Sponsors:   Dimagi Inc.;   Dimagi Inc.;   Massachusetts General Hospital;   Boston University;   Boston Medical Center;   Harvard University;   National Institute of Mental Health (NIMH)
Not yet recruiting - verified June 2011

Conditions:   HIV Infection;   Bone Loss;   Osteopenia;   Osteoporosis
Intervention:   Drug: Zoledronic acid
Sponsors:   Emory University;   Emory University
Recruiting - verified March 2012

Condition:   Reduction in Heavy Drinking in Patients With HIV
Interventions:   Drug: Naltrexone;   Other: Placebo + Medication Management/Medication Coaching
Sponsors:   Yale University;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified January 2012

Conditions:   Fracture Fixation;   Intra-Articular Fractures;   Acetabulum
Intervention:   Biological: Vitagel topical surgical hemostat
Sponsors:   The University of Texas Health Science Center, Houston;   The University of Texas Health Science Center, Houston
Recruiting - verified June 2011

Conditions:   HIV Infections;   Heart Disease
Interventions:   Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
Sponsors:   University Hospitals of Cleveland;   University Hospitals of Cleveland;   National Institutes of Health (NIH);   AstraZeneca
Recruiting - verified January 2012

Condition:   HIV
Intervention:   Drug: Tenofovir/emtricitabine and raltegravir
Sponsors:   The University of Texas Health Science Center, Houston;   The University of Texas Health Science Center, Houston;   Merck;   Gilead Sciences
Recruiting - verified February 2012

Condition:   HIV Positive Patient Receive Implant Supported Restoration
Intervention:  
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   Astra Tech AB
Recruiting - verified February 2012

Conditions:   HIV;   Respiratory Infections;   Fungal Pneumonia;   Viral Pneumonia;   Mycobacteria
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID);   National Institutes of Health Clinical Center (CC)
Recruiting - verified July 2011

Conditions:   Anal Cancer;   Nonneoplastic Condition;   Penile Cancer;   Precancerous Condition
Interventions:   Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer
Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Pregnancy Outcome
Intervention:  
Sponsors:   Microbicide Trials Network;   Microbicide Trials Network;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institutes of Health (NIH);   Gilead Sciences;   CONRAD
Recruiting - verified August 2011

Conditions:   LAD-1;   DOCK8;   MonoMAC
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   HIV;   AIDS
Intervention:  
Sponsors:   George Washington University;   George Washington University;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Conditions:   Human Immunodeficiency Virus (HIV);   Hepatitis C, Chronic
Intervention:  
Sponsors:   George Washington University;   George Washington University
Recruiting - verified September 2010

Conditions:   HIV;   Cancer
Intervention:   Biological: Fluzone High Dose Vaccine Vs Fluzone
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
Recruiting - verified April 2012

Condition:   HIV
Intervention:   Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute on Drug Abuse (NIDA);   National Institute of Mental Health (NIMH)
Recruiting - verified January 2011

Condition:   HIV
Intervention:   Procedure: Lymph node biopsy
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Institutes of Health (NIH)
Recruiting - verified March 2012

Condition:   HIV Infections
Interventions:   Behavioral: Affect Management;   Behavioral: General Health Promotion
Sponsors:   Rhode Island Hospital;   Rhode Island Hospital
Recruiting - verified July 2011

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Biological: rituximab;   Drug: EPOCH regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat;   Other: R-CHOP regimen
Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Stage IIIc/IV Melanoma
Intervention:   Biological: Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand
Sponsors:   Baylor Research Institute;   Baylor Research Institute;   National Institutes of Health (NIH);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   HIV;   Sexually Transmitted Diseases
Interventions:   Behavioral: STYLEnS;   Behavioral: Health Promotion
Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute
Recruiting - verified March 2012

Conditions:   Hepatitis C;   HIV
Intervention:   Drug: Pegylated interferon with ribavirin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID);   Fundacion de Investigacion de Diego
Recruiting - verified April 2012

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV);   Drug: tenofovir/emtricitabine (TDF/FTC);   Drug: Atazanavir (ATV);   Drug: Ritonavir;   Procedure: Phlebotomy
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Society of Infectious Diseases Pharmacists;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Condition:   Hepatitis B
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified May 2012

Conditions:   Substance Abuse;   Contingency Management;   Exercise
Intervention:   Behavioral: Contingency Management
Sponsors:   University of Connecticut Health Center;   University of Connecticut Health Center;   National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011

Condition:   Healthy Adult Females
Intervention:   Other: Pharmacokinetic Sampling
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill
Recruiting - verified March 2012

Condition:   HIV-1 Infection
Intervention:   Biological: JS7 plasmid DNA and MVA62B vaccine
Sponsors:   GeoVax, Inc.;   GeoVax, Inc.;   AIDS Research Consortium of Atlanta;   University of Alabama at Birmingham;   AIDS Research Alliance
Recruiting - verified December 2011

Condition:   HIV
Intervention:   Drug: Lopinavir/ritonavir
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Risk Reduction Behavior;   Health Behavior;   Sexual Behavior;   Adolescent Behavior;   Cannabis
Interventions:   Behavioral: INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY);   Behavioral: SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH);   Behavioral: SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION
Sponsors:   University of New Mexico;   University of New Mexico;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011

Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
Interventions:   Drug: CD8+ young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Anal Cancer;   Neoplasm of Uncertain Malignant Potential;   Nonneoplastic Condition;   Precancerous Condition
Interventions:   Other: clinical observation;   Procedure: infrared photocoagulation therapy
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   HIV Infection
Intervention:   Drug: Raltegravir
Sponsors:   Southern California Institute for Research and Education;   Southern California Institute for Research and Education;   Merck
Recruiting - verified May 2012

Condition:   Contraception
Interventions:   Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2;   Drug: levonorgestrel patch with BMI <32 kg/m2;   Drug: levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2;   Drug: levonorgestrel patch with BMI <32 kg/m2
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Health Decisions
Recruiting - verified February 2012

Condition:   HIV
Interventions:   Behavioral: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test;   Device: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Sponsors:   University of Washington;   University of Washington;   Public Health - Seattle and King County;   National Institute of Mental Health (NIMH)
Recruiting - verified February 2012

Conditions:   HIV;   AIDS;   Epidemiology;   Prevention
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting - verified April 2012

Conditions:   HIV+;   Fatigue;   Unmet Vocational Goals
Interventions:   Behavioral: Behavioral Activation Therapy-;   Behavioral: Supportive Counseling
Sponsors:   Research Foundation for Mental Hygiene;   Research Foundation for Mental Hygiene
Recruiting - verified November 2011

Condition:   HIV Infection
Interventions:   Behavioral: Linkage-to-Care Component: Financial Incentive (FI);   Behavioral: Linkage-to-Care Component: Standard of Care (SOC);   Behavioral: Viral Suppression Component: FI;   Behavioral: Viral Suppression Component: SOC;   Behavioral: Prevention for Positives Component: Counseling and SOC;   Behavioral: Prevention for Positives Component: SOC
Sponsors:   HIV Prevention Trials Network;   HIV Prevention Trials Network;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012

Condition:   HIV Positive
Intervention:  
Sponsors:   University of California, San Diego;   Zuniga De Nuncio, Maria;   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2012

Condition:   Non-Hodgkin's Lymphoma
Interventions:   Drug: G-CSF (filgrastim) plus Plerixafor Injection;   Drug: G-CSF (filgrastim) plus Plerixafor Injection
Sponsors:   Genzyme;   Genzyme
Recruiting - verified April 2012

Condition:   Acute Myelogenous Leukemia
Interventions:   Drug: Plerixafor;   Drug: Clofarabine
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Genzyme
Recruiting - verified April 2012

Condition:   Drug Usage
Intervention:  
Sponsors:   University of Michigan;   University of Michigan;   National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2011

Conditions:   Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Lymphoma, Non-Hodgkin;   Hodgkin Disease;   Leukemia, Lymphocytic, Chronic, B-Cell;   Multiple Myeloma
Intervention:   Drug: Sargramostim and plerixafor
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified November 2011

Condition:   Major Depression
Interventions:   Behavioral: Interpersonal Psychotherapy;   Behavioral: Problem-Solving Therapy;   Behavioral: Brief Supportive Psychotherapy
Sponsors:   New York State Psychiatric Institute;   New York State Psychiatric Institute
Recruiting - verified February 2012

Conditions:   HIV Infections;   Menopause
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
Recruiting - verified January 2012

Conditions:   HIV Infections;   Hepatitis;   Sexually Transmitted Infections
Interventions:   Behavioral: Traditional Prevention;   Behavioral: Web-based Prevention
Sponsors:   National Development and Research Institutes, Inc.;   National Development and Research Institutes, Inc.;   National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011

Conditions:   Lymphoma;   HIV
Intervention:   Procedure: Autologous transplant
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified January 2012

Conditions:   HIV;   AIDS
Intervention:   Behavioral: Skills Building - Motivational Interviewing
Sponsors:   Boston Medical Center;   Boston Medical Center
Recruiting - verified June 2011

Conditions:   Stimulant-Related Disorders;   HIV;   HIV Infections
Intervention:   Drug: Truvada
Sponsors:   Friends Research Institute, Inc.;   Friends Research Institute, Inc.;   University of California, Los Angeles
Recruiting - verified October 2011

Conditions:   HIV-1 Infection;   Neuropathic Pain
Intervention:   Drug: pregabalin (Lyrica)
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Drug: Tenofovir 1% gel;   Other: Placebo gel
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Drug Abuse;   HIV Risk Behavior
Interventions:   Behavioral: Computerized brief intervention;   Behavioral: Counselor delivered brief intervention
Sponsors:   Friends Research Institute, Inc.;   Friends Research Institute, Inc.;   National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011

Conditions:   Hazardous Alcohol Use;   Binge Drinking;   High Risk Sexual Behaviors;   HIV Risk Reduction;   HIV Infection
Interventions:   Behavioral: Computerized brief alcohol intervention with IVR booster calls;   Behavioral: Computer delivered brief alcohol intervention;   Behavioral: Attention Control
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Not yet recruiting - verified June 2011

Conditions:   HIV Medication Adherence;   Methamphetamine Use;   Sexual Risk;   Poly-substance Use;   HIV Infections
Interventions:   Behavioral: Motivational Interviewing + Cognitive Behavioral Skills Training;   Behavioral: Education Attention Control
Sponsors:   Hunter College;   Hunter College
Recruiting - verified June 2011

Conditions:   Substance Abuse;   HIV Infections
Intervention:   Behavioral: Stonewall Project
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   California HIV/AIDS Research Program
Recruiting - verified March 2012

Condition:   Normal Volunteer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Condition:   Drug Abuse
Interventions:   Behavioral: Computer-delivered Brief Intervention (CBI);   Behavioral: Intervener-delivered Brief Intervention (IBI);   Behavioral: Adapted Motivational Enhancement Therapy (AMET);   Behavioral: Enhanced Usual Care (EUC)
Sponsors:   University of Michigan;   University of Michigan;   National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012

Condition:   HIV-1 Infections
Interventions:   Drug: Darunavir;   Drug: ritonavir;   Drug: ritonavir;   Drug: Darunavir;   Drug: ritonavir;   Drug: Darunavir;   Drug: Darunavir;   Drug: Darunavir;   Drug: ritonavir;   Drug: Darunavir;   Drug: ritonavir;   Drug: Darunavir;   Drug: Darunavir;   Drug: ritonavir
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified May 2012

Condition:   Non Small Cell Lung Cancer
Intervention:   Drug: Nelfinavir
Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified January 2012

Conditions:   Birth Defects;   Infection, Human Immunodeficiency Virus
Intervention:   Drug: Any Antiretroviral Therapy
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   GlaxoSmithKline
Recruiting - verified February 2012

Conditions:   Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
Interventions:   Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   HIV Infections
Intervention:   Procedure: Blood collection
Sponsors:   GlaxoSmithKline;   GlaxoSmithKline
Recruiting - verified April 2012

Conditions:   HIV;   Cardiovascular Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011

Conditions:   Adult Non-Hodgkin Lymphoma;   Adult Grade III Lymphomatoid Granulomatosis;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
Interventions:   Biological: filgrastim;   Drug: plerixafor;   Biological: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide;   Procedure: leukapheresis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Myeloma;   Lymphoma
Intervention:   Drug: Plerixafor
Sponsors:   Emory University;   Emory University;   Genzyme
Recruiting - verified March 2012

Conditions:   HIV;   HIV Infections
Intervention:  
Sponsors:   George Washington University;   George Washington University
Recruiting - verified September 2010

Conditions:   Alcohol Dependence;   Problem Drinking;   Hazardous Drinking;   Human Immunodeficiency Virus;   AIDS
Interventions:   Drug: Vivitrol- Intramuscular naltrexone (depot-formulation);   Drug: Placebo
Sponsors:   Yale University;   Yale University;   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified August 2011

Condition:   Lymphoma
Interventions:   Drug: lenalidomide;   Drug: temsirolimus;   Other: enzyme-linked immunosorbent assay;   Other: flow cytometry;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI)
Recruiting - verified November 2010

Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Brain Stem Glioma;   Ependymoblastoma;   Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma;   Grade III Meningioma;   Meningeal Hemangiopericytoma;   Mixed Glioma;   Pineal Gland Astrocytoma;   Brain Tumor
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
Recruiting - verified November 2011

Condition:   HIV Infection
Interventions:   Biological: AGS-004;   Biological: Placebo
Sponsors:   Argos Therapeutics;   Argos Therapeutics
Recruiting - verified November 2011

Conditions:   Bone Marrow;   Bone Marrow Stromal Cells;   Mesenchymal Stem Cells;   Blood Donors
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified November 2011

Conditions:   Carcinoma, Adenoid Cystic;   Head and Neck Neoplasms
Intervention:   Drug: Nelfinavir
Sponsors:   University of Iowa;   University of Iowa;   Holden Comprehensive Cancer Center
Recruiting - verified March 2012

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
Intervention:   Drug: Plerixafor
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   Genzyme
Recruiting - verified May 2012

Conditions:   HIV;   HIV Infections
Intervention:   Drug: Valacyclovir
Sponsors:   University of Washington;   University of Washington
Recruiting - verified November 2011

Conditions:   Nonneoplastic Condition;   Sarcoma
Interventions:   Drug: lenalidomide;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Adenocarcinoma of the Pancreas;   Pancreatic Cancer;   Stage III Pancreatic Cancer
Interventions:   Drug: gemcitabine hydrochloride;   Drug: leucovorin calcium;   Drug: fluorouracil;   Drug: nelfinavir mesylate;   Radiation: stereotactic body radiation therapy;   Radiation: hypofractionated radiation therapy;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Genetic: polymorphism analysis;   Other: pharmacogenomic studies;   Genetic: protein expression analysis
Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Myelodysplastic Syndromes
Interventions:   Drug: G-CSF, Plerixafor and Azacitidine;   Drug: G-CSF, Plerixafor and Azacitidine;   Drug: G-CSF, Plerixafor and Azacitidine
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Conditions:   Influenza;   (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   National Institutes of Health (NIH)
Recruiting - verified April 2012

Condition:   Influenza
Intervention:  
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   National Institutes of Health (NIH)
Recruiting - verified April 2012

Conditions:   HIV Infection;   HIV Infections
Intervention:   Genetic: SB-728-T
Sponsors:   Sangamo Biosciences;   Sangamo Biosciences
Recruiting - verified December 2011

Conditions:   HIV Infection;   HIV Infections
Intervention:  
Sponsors:   Merck;   Merck
Recruiting - verified May 2012

Condition:   Hepatitis C
Interventions:   Other: Ribavrin;   Drug: Abacavir plus Ribavirin
Sponsors:   Johns Hopkins University;   Johns Hopkins University;   GlaxoSmithKline;   University of Nebraska
Recruiting - verified January 2010

Condition:   Drug Abuse Among Patients Admitted to a Trauma Department.
Interventions:   Behavioral: Brief advice;   Behavioral: Brief Intervention plus Booster Session (BMI+B);   Behavioral: Brief Intervention
Sponsors:   University of Texas at Austin;   University of Texas at Austin;   National Institute on Drug Abuse (NIDA)
Recruiting - verified May 2012

Conditions:   High Triglyceride Level;   HIV Infection
Intervention:   Drug: Lovaza
Sponsors:   Tufts University;   Todd Conley;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011

Condition:   HIV Infections
Interventions:   Drug: Emtricitabine (FTC);   Drug: Tenofovir disoproxil fumarate (TDF);   Drug: Efavirenz (EFV)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Multiple Myeloma;   Non-Hodgkins Lymphoma
Intervention:   Drug: Plerixafor
Sponsors:   Shi, Patricia, M.D.;   Shi, Patricia, M.D.;   Genzyme
Recruiting - verified September 2011

Conditions:   HIV Infections;   Acquired Immunodeficiency Syndrome;   Medication Adherence
Intervention:   Behavioral: MedCHEC tablet computer and Adherence Care
Sponsors:   Boston University;   Boston University;   National Institute of Mental Health (NIMH);   Department of Veterans Affairs;   VA Boston Healthcare System;   VA Greater Los Angeles Healthcare System;   San Diego State University;   Tufts University
Recruiting - verified February 2012

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2011

Condition:   HIV Infections
Intervention:  
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Aldesleukin
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified January 2012

Conditions:   HIV Infection;   Osteopenia;   Osteoporosis
Intervention:  
Sponsors:   Emory University;   Emory University;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified March 2012

Conditions:   HIV Infections;   Hepatitis C Virus
Intervention:  
Sponsors:   Rockefeller University;   Rockefeller University
Recruiting - verified February 2012

Conditions:   Melanoma;   Carcinoma, Renal Cell
Intervention:   Drug: Recombinant Human IL-15
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Sarcoma
Interventions:   Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Stem Cell Transplant Patients
Intervention:   Drug: G-CSF +/- AMD3100
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified September 2011

Condition:   HIV Infections
Interventions:   Other: CARE+ Spanish computer counseling session;   Other: CARE+ Spanish brief computer risk assessment session
Sponsors:   New York University;   New York University;   St. Luke's-Roosevelt Hospital Center
Recruiting - verified February 2012

Condition:   Breast Cancer
Interventions:   Drug: ritonavir;   Procedure: therapeutic conventional surgery
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   Susan G. Komen Breast Cancer Foundation
Recruiting - verified January 2012

Condition:   Substance Use Disorder
Interventions:   Behavioral: Computerized brief intervention;   Behavioral: Computerized health screening;   Behavioral: Computerized assessment;   Behavioral: Therapist-delivered motivational intervention
Sponsors:   Virginia Commonwealth University;   Virginia Commonwealth University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011

Condition:   Trichomonas Infections
Intervention:  
Sponsors:   University of Mississippi Medical Center;   University of Mississippi Medical Center;   Mississippi State Department of Health
Recruiting - verified April 2012

Condition:   Influenza Virus
Intervention:  
Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
Recruiting - verified May 2012

Condition:   HIV Infections
Intervention:   Behavioral: Modified client adherence profiling and intervention tailoring (CAP-IT)
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   HIV Infections
Interventions:   Biological: WT-gag-TCR modified T cells;   Biological: α/6-gag-TCR modified T cells;   Other: STI or Drug Holiday
Sponsors:   University of Pennsylvania;   University of Pennsylvania;   Adaptimmune Ltd.
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Behavioral: Enhanced nursing telephone support;   Behavioral: Standard care
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   Opiate Dependence
Intervention:   Behavioral: Linkage
Sponsors:   Butler Hospital;   Butler Hospital;   Boston Medical Center
Recruiting - verified March 2012

Condition:   High Risk Non-Hodgkin's Lymphoma
Interventions:   Biological: Rituximab;   Biological: Interleukin-2
Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
Recruiting - verified April 2012

Condition:   Hepatitis B
Interventions:   Drug: Simvastatin;   Drug: Tenofovir;   Drug: Entecavir
Sponsors:   Bader, Ted, M.D.;   Bader, Ted, M.D.
Recruiting - verified June 2011

Conditions:   HIV Infections;   HIV-1
Intervention:   Drug: Etravirine
Sponsors:   Janssen R&D Ireland;   Janssen R&D Ireland
Recruiting - verified April 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Plerixafor
Sponsors:   Genzyme;   Genzyme
Recruiting - verified January 2012

Conditions:   Lymphoma;   Nonneoplastic Condition
Interventions:   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Kaposi's Sarcoma;   Gastric Cancer;   Nasopharyngeal Cancer
Interventions:   Other: FIAU-PET-CT scans;   Other: FIAU-PET-CT scan
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Drug: Raltegravir (RAL);   Drug: Atazanavir (ATV);   Drug: Ritonavir (RTV);   Drug: Tenofovir (TDF);   Drug: Etravirine (ETV);   Drug: Darunavir (DRV);   Drug: Maraviroc (MVC);   Drug: Lopinavir/ritonavir (LPV/r)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Infertility;   HIV Infections
Interventions:   Other: Sperm washing and testing for HIV contamination;   Procedure: Intrauterine Insemination
Sponsors:   University of Missouri-Columbia;   University of Missouri-Columbia
Available - verified September 2011

Conditions:   Malaria;   Malaria Vaccines;   Plasmodium Falciparum Malaria
Intervention:   Biological: Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine
Sponsors:   National Institutes of Health Clinical Center (CC);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified March 2011

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   HIV-associated Hodgkin Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Secondary Myelodysplastic Syndromes
Interventions:   Procedure: leukapheresis;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Other: laboratory biomarker analysis;   Other: DNA analysis;   Other: RNA analysis;   Other: flow cytometry;   Other: reverse transcriptase-polymerase chain reaction;   Other: nucleic acid sequencing;   Other: protein expression analysis
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Cardiovascular Disease;   HIV;   Atherosclerosis;   Inflammation;   Statins, HMG-CoA;   HIV Infections
Interventions:   Drug: atorvastatin;   Drug: Placebo
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   WHIMS;   Neutrophil Disorder;   Myelokathexis;   Hypogammaglobulinemia
Intervention:   Drug: Mozobil (TM)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   HIV Infections
Intervention:   Drug: Etravirine (Intelence)
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Janssen Pharmaceuticals
Recruiting - verified December 2011

Conditions:   Lymphoma;   B-cell Lymphoma
Interventions:   Procedure: Leukapheresis;   Procedure: Stem Cell Transplant;   Procedure: CD19-specific T Cell Infusion;   Drug: IL-2;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Drug: Rituximab
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   HIV Infections
Intervention:   Drug: Highly active antiretroviral therapy (HAART)
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Biological: VRC-HIVDNA-016-00-VP;   Biological: VRCHIVADV014-00-VP
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Cystitis;   Bladder Diseases
Intervention:   Drug: Cidofovir
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Gilead Sciences
Not yet recruiting - verified March 2012

Conditions:   Acute Myelogenous Leukemia;   Leukemia
Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Drug: Sorafenib
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bayer;   Genzyme;   Onyx Pharmaceuticals
Recruiting - verified February 2012

Conditions:   Acute HIV Infection;   HIV Infections
Intervention:   Drug: Atripla
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Bristol-Myers Squibb;   Gilead Sciences
Recruiting - verified December 2011

Condition:   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Sarcoma, Kaposi
Interventions:   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Oncology
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   HIV Infections
Interventions:   Drug: Alendronate;   Drug: Alendronate placebo;   Dietary Supplement: Calcium carbonate/vitamin D
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012

Condition:   HIV Infection
Intervention:  
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011

Condition:   HIV Infections
Intervention:   Biological: SAV001-H
Sponsors:   Sumagen;   Sumagen
Recruiting - verified March 2012

Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions:   Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Renal Cancer;   Kidney Cancer
Interventions:   Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified October 2011

Condition:   Opiate Addiction
Interventions:   Other: Brief Intervention with Buprenorphine initiation;   Behavioral: Brief Intervention
Sponsors:   Yale University;   Yale University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified December 2011

Condition:   Multiple Myeloma
Interventions:   Drug: Plerixafor (AMD3100);   Drug: bortezomib
Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Genzyme
Recruiting - verified May 2012

Condition:   Leukemia, Myeloid, Acute
Interventions:   Drug: G-CSF;   Drug: Plerixafor;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Conditions:   Cryptococcal Meningitis;   HIV Infections
Interventions:   Drug: Fluconazole;   Drug: Amphotericin B
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   Autoinflammatory Syndromes;   Physical Urticaria
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011

Conditions:   HIV Infections;   Drug Abuse
Interventions:   Drug: Disulfiram;   Drug: Disulfiram + Efavirenz;   Drug: Disulfiram + Atazanavir;   Drug: Disulfiram + Ritonavir
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011

Condition:   HIV Infections
Intervention:   Behavioral: Entre Culturas: Navigating Culture, Identity, and HIV Risk
Sponsors:   Nova Southeastern University;   Nova Southeastern University
Recruiting - verified November 2011

Conditions:   HIV Infections;   Hepatitis C
Interventions:   Drug: Alcohol;   Drug: Alcohol placebo
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified April 2012

Condition:   HIV Infection
Intervention:   Drug: All licensed antiretroviral medications
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Minnesota - Clinical and Translational Science Institute;   National Institute of Allergy and Infectious Diseases (NIAID);   Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark;   Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom;   Kirby Institute;   The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA;   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   German Federal Ministry of Education and Research;   NEAT - European AIDS Treatment Network;   National Health and Medical Research Council, Australia;   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI);   National Institute of Mental Health (NIMH);   National Institute of Neurological Disorders and Stroke (NINDS);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   Abbott;   Bristol-Myers Squibb;   Gilead Sciences;   GlaxoSmithKline;   Merck;   Tibotec Pharmaceutical Limited
Recruiting - verified April 2012

Condition:   HIV Infections
Interventions:   Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Vaccine Trials Network
Recruiting - verified May 2012

Conditions:   Idiopathic CD4+ Lymphocytopenia;   Cryptococcal Meningitis;   Warts
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   Recurrent Melanoma;   Stage IV Melanoma
Interventions:   Biological: ipilimumab;   Drug: cyclophosphamide;   Procedure: biopsy;   Biological: aldesleukin;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Biological: therapeutic allogeneic cytotoxic T lymphocytes
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   HIV (Human Immunodeficiency Virus);   Metabolic Syndrome;   HIV Infections
Intervention:   Behavioral: Dietary Intervention
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified June 2011

Conditions:   Acute HIV Infection;   HIV Infections
Intervention:   Drug: Darunavir/Ritonavir and Etravirine
Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Janssen Pharmaceuticals
Recruiting - verified December 2011

Conditions:   HIV;   HIV Infections;   Pregnancy
Interventions:   Drug: TMC114 (darunavir);   Drug: ritonavir;   Drug: TMC125 (etravirine);   Drug: TMC278 (rilpivirine);   Drug: TMC114 (darunavir)
Sponsors:   Tibotec, Inc;   Tibotec, Inc;   Janssen Services, LLC
Recruiting - verified May 2012

Conditions:   HIV;   HIV Infections
Intervention:   Behavioral: Video
Sponsors:   North Bronx Healthcare Network;   North Bronx Healthcare Network;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified August 2011

Conditions:   HIV Infections;   Sexually Transmitted Infections
Interventions:   Behavioral: Male Sexual Health Program;   Behavioral: Focus on the Future Program
Sponsors:   University of Kentucky;   University of Kentucky;   Louisiana State University Health Sciences Center in New Orleans;   Carolinas Healthcare System
Recruiting - verified August 2011

Conditions:   HIV Infection;   Cardiovascular Disease;   Inflammation;   HIV Infections
Interventions:   Drug: Maraviroc;   Drug: placebo
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI);   Pfizer
Recruiting - verified November 2011

Conditions:   HIV Infection;   Inflammation;   Cardiovascular Disease;   HIV Infections
Interventions:   Drug: raltegravir;   Drug: Placebo
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Heart, Lung, and Blood Institute (NHLBI);   Merck
Recruiting - verified November 2011

Conditions:   HIV;   Substance Abuse;   HIV Infections
Interventions:   Behavioral: Intensive Case Management;   Drug: Buprenorphine;   Behavioral: Money Management
Sponsors:   Yale University;   Yale University
Recruiting - verified June 2011

Condition:   Idiopathic CD4+ T-Lymphocytopenia
Intervention:   Drug: CYT107
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified September 2011

Condition:   Substance Abuse
Intervention:   Behavioral: contingency management
Sponsors:   University of Connecticut Health Center;   University of Connecticut Health Center;   National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011

Condition:   HIV-1
Interventions:   Drug: UK-453,061 Dose 1;   Drug: UK-453,061 Dose 2;   Drug: Etravirine
Sponsors:   Pfizer;   Pfizer
Recruiting - verified May 2012

Condition:   HIV-1
Interventions:   Drug: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed;   Other: Standard of care tests if needed
Sponsors:   Pfizer;   Pfizer
Recruiting - verified April 2012

Conditions:   Cancer;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified October 2011

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   HIV Infections
Interventions:   Drug: Chloroquine;   Drug: Placebo
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Conditions:   Acquired Immune Deficiency Syndrome;   AIDS;   Human Immunodeficiency Virus;   HIV Infections
Interventions:   Drug: Raltegravir;   Drug: Atazanavir;   Other: Standard treatment regimen
Sponsors:   Yale University;   Yale University;   Bristol-Myers Squibb;   Merck
Recruiting - verified February 2012

Conditions:   HSV-2;   HIV;   HIV Infections
Interventions:   Drug: Valacyclovir;   Drug: Placebo
Sponsors:   University of Alabama at Birmingham;   University of Alabama at Birmingham;   GlaxoSmithKline
Recruiting - verified August 2011

Conditions:   HIV Infections;   HIV-1
Intervention:   Drug: TMC278
Sponsors:   Tibotec Pharmaceuticals, Ireland;   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2012

Condition:   HIV Lipodystrophy
Interventions:   Drug: Growth hormone;   Drug: Growth Hormone Releasing Hormone
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified April 2012

Condition:   Human Immunodeficiency Virus (HIV)
Intervention:   Drug: Maraviroc
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Pfizer
Recruiting - verified May 2012

Conditions:   HIV Infections;   AIDS;   Opportunistic Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Cocaine Dependence;   Cocaine-Related Disorders;   Opioid-Related Disorders
Interventions:   Drug: Airipiprazole;   Drug: Placebo
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute on Drug Abuse (NIDA)
Recruiting - verified July 2011

Conditions:   Cardiovascular Disease;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012

Condition:   Breast Cancer
Interventions:   Biological: allogeneic large multivalent immunogen breast cancer vaccine;   Biological: aldesleukin
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified May 2012

Condition:   HIV Infection
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011

Condition:   Human Immunodeficiency Virus Infections
Intervention:   Behavioral: Questionnaire
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Conditions:   Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention:   Other: educational intervention
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   HIV
Intervention:   Behavioral: Online social networking HIV prevention
Sponsors:   Colorado School of Public Health;   Colorado School of Public Health;   National Institute of Nursing Research (NINR);   Internet Sexuality Information Services (ISIS);   Columbia University;   Rutgers University
Recruiting - verified July 2009

Conditions:   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions:   Drug: AMD3100;   Drug: G-CSF;   Procedure: Apheresis
Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
Recruiting - verified October 2011

Conditions:   Substance Abuse;   HIV Infections
Interventions:   Behavioral: contingency management;   Behavioral: contingency management
Sponsors:   University of Connecticut Health Center;   University of Connecticut Health Center;   National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011

Conditions:   Smoking;   HIV Infections
Interventions:   Drug: Varenicline tartrate;   Drug: Nicotine Replacement Therapy;   Other: Biological Control;   Behavioral: Motivational Interview
Sponsors:   Ohio State University;   Ohio State University;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011

Conditions:   Aids-related Malignancies;   Lymphoma;   Precancerous Condition;   Sarcoma
Interventions:   Genetic: polymerase chain reaction;   Other: cytology specimen collection procedure;   Other: histological technique;   Procedure: colposcopic biopsy
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Pulmonary Tuberculosis
Interventions:   Drug: rifampin;   Drug: rifapentine;   Drug: rifapentine;   Drug: rifapentine
Sponsors:   Centers for Disease Control and Prevention;   Centers for Disease Control and Prevention;   Sanofi-Aventis
Recruiting - verified May 2012

Condition:   Human Immunodeficiency Virus
Interventions:   Drug: Maraviroc along with an optimized background antiretroviral drug regimen;   Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors:   ViiV Healthcare;   ViiV Healthcare;   Pfizer
Recruiting - verified May 2012

Condition:   HIV Infections
Intervention:   Drug: ARV regimen chosen by treating physician
Sponsors:   University of North Carolina, Chapel Hill;   Kristine Patterson, MD;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012

Conditions:   HIV Infections;   Hyperlipidemia
Intervention:   Drug: Atorvastatin
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012

Conditions:   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Metastatic Cancer
Interventions:   Biological: therapeutic autologous lymphocytes;   Biological: aldesleukin;   Drug: cyclophosphaide;   Drug: fludarabine phosphate
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified November 2011

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: carboplatin;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Genetic: polymerase chain reaction;   Genetic: western blotting
Sponsors:   AIDS Malignancy Clinical Trials Consortium;   AIDS Malignancy Clinical Trials Consortium;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Cocaine Addiction
Interventions:   Behavioral: I/GDC + VR/CER;   Behavioral: I/GDC
Sponsors:   Duke University;   Duke University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified June 2011

Condition:   Lung Cancer
Interventions:   Biological: EGFRBi-armed autologous activated T cells;   Biological: aldesleukin;   Biological: sargramostim
Sponsors:   Roger Williams Medical Center;   Roger Williams Medical Center
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:   Drug: Cell Transfer
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified February 2012

Condition:   Opiate Dependence
Interventions:   Behavioral: Behavioral: Buprenorphine/naloxone maintenance (Mtn);   Behavioral: Behavioral: Buprenorphine/naloxone detoxification (Dtx)
Sponsors:   Yale University;   Yale University;   National Institute on Drug Abuse (NIDA)
Recruiting - verified November 2011

Condition:   Metastatic Melanoma
Intervention:   Drug: Proleukin and Dacarbazine
Sponsors:   James Graham Brown Cancer Center;   James Graham Brown Cancer Center
Recruiting - verified September 2011

Conditions:   Chronic Hepatitis B e Antigen Positive;   Chronic Hepatitis B e Antigen Negative
Intervention:   Drug: Tenofovir/ & Emtricitabine
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified November 2011

Condition:   HIV Infections
Interventions:   Drug: Raltegravir (MK-0518);   Drug: Raltegravir (MK-0518);   Drug: Raltegravir (MK-0518)
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012

Conditions:   HIV Infections;   Lipodystrophy
Intervention:   Drug: Metreleptin (Leptin)
Sponsors:   University of Texas Southwestern Medical Center;   University of Texas Southwestern Medical Center;   Amylin Pharmaceuticals, Inc.
Recruiting - verified August 2011

Conditions:   HIV-Dementia;   HIV-Associated Cognitive Motor Complex;   AIDS Encephalopathy;   AIDS Dementia Complex;   AIDS-Related Dementia Complex;   HIV Infections;   Healthy
Intervention:   Drug: [11C]PBR28
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Mental Health (NIMH)
Recruiting - verified August 2011

Condition:   HIV Infections
Interventions:   Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Bill and Melinda Gates Foundation
Recruiting - verified May 2012

Conditions:   HIV Infections;   Coronary Atherosclerosis
Intervention:  
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Bristol-Myers Squibb
Recruiting - verified February 2012

Condition:   Vaccine
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified February 2012

Conditions:   Oral Hygiene;   HIV Infections;   Mouth Diseases
Intervention:   Behavioral: Case-management linkage intervention
Sponsors:   University of Miami;   University of Miami;   National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified January 2012

Condition:   Cocaine Dependence
Interventions:   Drug: Modafinil;   Drug: placebo;   Behavioral: Cognitive Behavioral Therapy (CBT)
Sponsors:   University of Pennsylvania;   University of Pennsylvania
Recruiting - verified November 2011

Condition:   Lymphoma
Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy;   Biological: G-CSF
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012

Condition:   Pneumocystis Pneumonia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011

Condition:   CMV Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Condition:   Samples
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified August 2011

Condition:   Liver Fibrosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Condition:   Severe Hemophilia A
Intervention:   Drug: Alphanate SD/HT
Sponsors:   Grifols Biologicals Inc.;   Grifols Biologicals Inc.
Recruiting - verified March 2012

Condition:   Stem Cell Mobilization
Intervention:   Drug: AMD3100
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012

Conditions:   Metastatic Melanoma;   Renal Cell Cancer
Intervention:   Biological: aldesleukin
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified July 2011

Condition:   Opioid-Related Disorders
Interventions:   Drug: Clonidine;   Drug: Placebo
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Condition:   Melanoma
Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Chiron Corporation
Recruiting - verified March 2012

Conditions:   AIDS-Related Primary Central Nervous System Lymphoma;   HIV
Interventions:   Drug: Methotrexate;   Biological: rituximab;   Procedure: antiviral therapy;   Drug: leucovorin calcium
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:   Procedure: blood draw
Sponsors:   Rockefeller University;   Rockefeller University
Recruiting - verified January 2012

Conditions:   Drug Abuse;   HIV Infections
Intervention:  
Sponsors:   University of Florida;   University of Florida;   National Institute on Drug Abuse (NIDA);   Johns Hopkins University
Recruiting - verified March 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   University of California, San Francisco;   University of California, San Francisco;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012

Condition:   Myelodysplastic Syndromes
Intervention:   Drug: Alemtuzumab (Campath)
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012

Condition:   HIV Infection
Intervention:   Drug: Efavirenz
Sponsors:   Bristol-Myers Squibb;   Bristol-Myers Squibb
Available - verified January 2012

Condition:   Blood Component Removal
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Primary CNS Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   HIV Infection;   HIV-associated Hodgkin Lymphoma;   Intraocular Lymphoma;   Isolated Plasmacytoma of Bone;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Meningeal Chronic Myelogenous Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Lymphoma;   Primary Myelofibrosis;   Primary Systemic Amyloidosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenstrom Macroglobulinemia
Interventions:   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: allogeneic bone marrow transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Hemoglobinopathies;   Hemolysis;   Iron Deficiency and Overload;   Anemias
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011

Condition:   Giant Lymph Node Hyperplasia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Healthy
Intervention:   Drug: AMD3100
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified November 2011

Conditions:   Hepatitis C;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Healthy;   Blood Component Removal
Intervention:   Drug: AMD3100
Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified August 2011

Condition:   Blood Component Removal
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Condition:   HIV Infections
Intervention:   Drug: Tipranavir
Sponsors:   Boehringer Ingelheim Pharmaceuticals;   Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012

Conditions:   Urticaria;   Arthropathy;   Lymphadenopathy;   Nervous System Anomalies
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Condition:   HIV Infections
Intervention:   Drug: Current ARV medications
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2011

Condition:   HIV Infections
Intervention:  
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Conditions:   HIV Seronegativity;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Conditions:   Rheumatic Diseases;   Healthy
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified January 2012

Condition:   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Conditions:   HIV Infections;   Pregnancy Complications, Infectious
Intervention:   Behavioral: Adherence assessment
Sponsors:   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   International Maternal Pediatric Adolescent AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified May 2012

Conditions:   Cancer;   HIV Infection;   Skin Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Virus Disease
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified May 2012

Condition:   Severe Combined Immunodeficiency Syndrome
Intervention:   Drug: CD34+ cells transduced with ADA retrovir
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified February 2012

Condition:   Common Variable Immunodeficiency
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2011

Condition:   Head and Neck Cancer
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute on Deafness and Other Communication Disorders (NIDCD)
Recruiting - verified July 2011

Condition:   Hemochromatosis
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institutes of Health Clinical Center (CC)
Recruiting - verified August 2011

Conditions:   HIV Infection;   Kaposi's Sarcoma
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified September 2011

Conditions:   AIDS Related Lymphoma;   HIV Infection
Interventions:   Biological: Rituximab;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Immunologic Deficiency Syndrome
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Human Genome Research Institute (NHGRI)
Recruiting - verified July 2011

Condition:   HIV Infections
Intervention:  
Sponsors:   AIDS Clinical Trials Group;   AIDS Clinical Trials Group;   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 2012

Condition:   HIV Infection
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID);   Washington Hospital Center
Recruiting - verified January 2012

Conditions:   HIV Infection;   Viremia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011

Conditions:   HIV Infection;   Immunologic Deficiency Syndrome
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012

Conditions:   AIDS Associated Nephropathy;   Focal Glomerulosclerosis;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified July 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified August 2011

Condition:   HIV Infection
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified March 2012

Conditions:   AIDS Associated Nephropathy;   Focal Glomerulosclerosis;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2011

Conditions:   Acquired Immunodeficiency Syndrome;   Neoplasm;   Skin Disease;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Acquired Immunodeficiency Syndrome;   Neoplasm;   Skin Disease;   HIV Infections
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified January 2012

Conditions:   HIV Infection;   Neoplasm
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Cryptococcosis;   Lymphopenia
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011

Conditions:   Alcoholic Intoxication;   Alcoholism;   Healthy
Intervention:  
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Recruiting - verified June 2011